KEY TAKEAWAY:Gilead, which recently acquired Kite Pharma in an all cash deal, said the list price for Yescarta, which is to be administered just once to each patient, would be $373,000. The cost is supposed to make us feel good because the price is well below that of the first drug in this new class such as $475,000 for Novartis’s Kymriah.
Fast Company found that women visit physicians more frequently and ask more questions after exams, especially expectant mothers. In addition, roughly 80 percent of healthcare decisions in households are made by women , and women are more likely to take care of family members when they get sick. Continue reading
According to the Atlantic “opioid abuse is rampant in states like Ohio, where paramedics are increasingly spending time responding to overdoses and where coroners’ offices are running out of room to store bodies. In 2012, there were 793 million doses of opioids prescribed in the state, enough to supply every man, woman, and child, with 68 pills each”. But is pharma really to blame? Continue reading
KEY TAKEAWAY: Assuming that consumers “tune out” or “tune in”risk information via DTC TV ads ignores one important aspect: consumers are not going to run to their doctor after seeing a DTC TV ad. Continue reading
According to CNN.com “The United States will not be escaping the obesity epidemic crisis anytime soon: Nearly 40% of adults and 19% of youth are obese, the highest rate the country has ever seen in all adults, according to research released Friday by the National Center for Health Statistics”. So who is responsible for telling patients to lose weight? Continue reading
As Trump dismantles the ACA pharma executives are once again taking the oath of silence. What is it going to take for these executives to come forward and inform the public that what Trump is doing could lead more chaos in our health care system? Continue reading
Ed Silverman at Pharmalot conducted a very revealing interview with California state senator Ed Hernandez, the Democratic legislator who “shepherded the California pharma pricing bill.”
Ed gamely tries to pin down Senator Hernandez on how exactly the bill will make a positive difference. Senator Hernandez seems unable to articulate any particular mechanism of action. His perspective appears to be: “Well, we did SOMETHING.” They did something because pharma companies have, for the most part, been ignoring the outrage over the high prices of drugs.